Evidence map›Paper›PMID 31281233›Full record

ArticleContrast media & molecular imaging2019

Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal

SiMin He, MingWei Wang, YongPing Zhang, JianMin Luo, YingJian Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. PET Imaging of Estrogen Receptors UsingMethods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Frontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

SiMin HeDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
MingWei WangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-0020-4700
YongPing ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
JianMin LuoDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
YingJian ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0001-6693-7494
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endocrine monotherapy of breast cancers is generally hampered by the primary/acquired resistance and adverse sides in clinical settings. Herein, advantaging the multitargeting antitumor effects and normal organ-protecting roles of Chinese herbal medicine, the aim of this study was to investigate the enhanced synergistic efficacy of fulvestrant plus Tan IIA combination therapy in ER-positive breast cancers and to monitor the early response by longitudinal

Indexed as

AbietanesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCell Line, TumorDrug CombinationsDrug MonitoringDrug SynergismEstrogen Receptor alphaFemaleFluorine RadioisotopesFulvestrantHumansMicePositron Emission Tomography Computed TomographyAbietanesDrug CombinationsESR1 protein, humanEstrogen Receptor alphaFluorine-18Fluorine RadioisotopesFulvestranttanshinone

Identifiers

PMID31281233
PMCPMC6590558
OpenAlexW2949491636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.